Based on these findings, the authors concluded that first-line EGFR-TKI treatment was generally associated with favorable survival outcomes in patients with postoperative recurrent EGFR-mutated lung adenocarcinoma. The gene discussed is EGFR; the disease is lung adenocarcinoma.